2026-08-10 · SEMAGLUTIDE · TopGLP1Providers Data Desk
Compounded semaglutide vs Wegovy: the shrinking gap, honestly priced
In August 2026 the cash-pay gap between FDA-approved Wegovy and compounded semaglutide was roughly $184–$216 a month; with NexLife at $109 (November 20, 2026) it is $240. NovoCare↗ sells Wegovy direct at $349 a month standard — $199 for the first two months at starter doses — and the oral Wegovy pill starts at $149. August captures ran $133 (Oak Longevity, limited states), $146 (Yucca) and $149 (OrderlyMeds↗); newer reads put Eden at $99 (October 15, 2026) and NexLife↗ at $109 (November 20, 2026, dose-flat, no membership). At a $240 monthly difference from NexLife, the approved product is a real choice for budgets that can stretch.
Released · Last reviewed · how we verify
What the extra money buys is not subtle: the exact formulation that produced Wegovy's trial results (roughly 15% average body-weight reduction in STEP-1), FDA manufacturing oversight, pharmacovigilance, and no dependence on the narrowed 503A lane compounded products now occupy. What compounded keeps: lower prices, dose-flat structures the pen system cannot match, no refill-timing rules, and — at programs like Henry ($149 start) or NexLife — formats like sublingual tablets for the needle-averse, though absorption for those routes is its own evidence question.
Annualized, the decision sharpens. A year of Wegovy at NovoCare's standard rate is $4,188 (less if your first two months catch the intro rate); a year of NexLife's compounded program is $1,308 billed month to month or $1,140 on its 12-month plan (read November 20, 2026); a year at Yucca was $1,752 in August. If insurance covers Wegovy at all, none of these cash numbers matter — and checking is exactly what an insurance-first program like Ro is for. If you are firmly cash-pay, the honest comparison is your dose path through the calculator, plus one non-financial line item: with the gap this small, the premium for the approved product is the cheapest insurance policy in the entire category. The days when compounded semaglutide was a quarter the price of brand are over; decide on the market as it is in 2026, not as it was in 2024.
Not medical advice; whether semaglutide in any form suits you is a clinician's call.